Comparative Pharmacology
Head-to-head clinical analysis: ISMOTIC versus MANNITOL 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ISMOTIC versus MANNITOL 5 IN PLASTIC CONTAINER.
ISMOTIC vs MANNITOL 5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Isosmotic solution of mannitol; increases plasma osmolality, drawing water from tissues into the vasculature and reducing intracranial/intraocular pressure via osmotic diuresis.
Mannitol is an osmotic diuretic that increases the osmolarity of the glomerular filtrate, reducing tubular reabsorption of water and solutes. It also draws water from intracellular spaces into the extracellular fluid, reducing cerebral edema and intraocular pressure.
1-2 g orally every 6-8 hours, maximum 8 g/day; or 1-2 g intravenously over 5-10 minutes every 6-8 hours, maximum 8 g/day.
50-100 g intravenously over 30-60 minutes for initial dose in acute renal failure or cerebral edema; maintenance dose 25-50 g every 6-8 hours based on serum osmolality and urine output.
None Documented
None Documented
4.5-6.0 hours in adults with normal renal function; prolonged in renal impairment (up to 24-48 hours in anuria)
Terminal elimination half-life: 1–2 hours (adults with normal renal function); prolonged to 24–48 hours in severe renal impairment.
Renal: 90-95% unchanged; biliary/fecal: <5%
Renal: >90% as unchanged drug via glomerular filtration; negligible biliary or fecal elimination.
Category C
Category A/B
Osmotic Diuretic
Osmotic Diuretic